Accordingly, activation of FXR results in a significant repression of cancer progression in liver and colon carcinomas [8, 12, 13], whereas inhibition of FXR suppress tumor progression in esophageal and pancreatic carcinomas [10, 11]. The gene discussed is NR1H4; the disease is cancer.